Proofreading-deficient coronaviruses adapt for increased fitness over long-term passage without reversion of exoribonuclease-inactivating mutations

mBio

Volumn 8, Issue 6, 2017, Pages

  Graepel, Kevin W ^a,b   Lu, Xiaotao ^b   Case, James Brett ^a,b   Sexton, Nicole R ^a,b   Smith, Everett Clinton ^b,c   Denisona, Mark R ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF THE SOUTH   (United States)

Author keywords

Adaptive evolution; Competitive fitness; Coronavirus; Exoribonuclease; Plus strand RNA virus; Proofreading; Replication fidelity; RNA virus

Indexed keywords

AZACITIDINE; EXORIBONUCLEASE; FLUOROURACIL; NONSTRUCTURAL PROTEIN 14; RIBAVIRIN; RNA DIRECTED RNA POLYMERASE; UNCLASSIFIED DRUG; VIRAL PROTEIN; VIRUS RNA; ANTIVIRUS AGENT;

AMINO ACID SUBSTITUTION; ANIMAL CELL; ARTICLE; CONTROLLED STUDY; CORONAVIRIDAE; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME ANALYSIS; GENOTYPE PHENOTYPE CORRELATION; MOLECULAR STABILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REPRODUCTIVE FITNESS; REVERTANT; VIRAL PHENOMENA AND FUNCTIONS; VIRUS CELL INTERACTION; VIRUS CULTURE; VIRUS GENOME; VIRUS MUTATION; VIRUS PROOFREADING; VIRUS REPLICATION; WILD TYPE; ANIMAL; CELL LINE; CORONAVIRINAE; CORONAVIRUS INFECTION; DRUG EFFECT; ENZYMOLOGY; GENETICS; GENOTYPE; METABOLISM; MOUSE; MUTATION; PATHOGENICITY; PHENOTYPE; VIROLOGY;

ANIMALS; ANTIVIRAL AGENTS; AZACITIDINE; CELL LINE; CORONAVIRUS; CORONAVIRUS INFECTIONS; EXORIBONUCLEASES; GENETIC FITNESS; GENOME, VIRAL; GENOTYPE; MICE; MUTATION; PHENOTYPE; RIBAVIRIN; RNA REPLICASE; RNA, VIRAL; VIRUS REPLICATION;

EID: 85039856776     PISSN: 21612129     EISSN: 21507511     Source Type: Journal    
DOI: 10.1128/mBio.01503-17     Document Type: Article

References (88)

1. Steinhauer DA, Domingo E, Holland JJ. 1992. Lack of evidence for proofreading mechanisms associated with an RNA virus polymerase. Gene 122:281-288. https://doi.org/10.1016/0378-1119(92)90216-C.
2. Sanjuan R, Nebot MR, Chirico N, Mansky LM, Belshaw R. 2010. Viral mutation rates. J Virol 84:9733-9748. https://doi.org/10.1128/JVI.00694-10.
3. Drake JW, Holland JJ. 1999. Mutation rates among RNA viruses. Proc Natl Acad Sci U S A 96:13910-13913. https://doi.org/10.1073/pnas.96.24.13910.
4. Bull JJ, Sanjuan R, Wilke CO. 2007. Theory of lethal mutagenesis for viruses. J Virol 81:2930-2939. https://doi.org/10.1128/JVI.01624-06.
5. Domingo E, Sheldon J, Perales C. 2012. Viral quasispecies evolution. Microbiol Mol Biol Rev 76:159-216. https://doi.org/10.1128/MMBR.05023-11.
6. Bradwell K, Combe M, Domingo-Calap P, Sanjuan R. 2013. Correlation between mutation rate and genome size in riboviruses: mutation rate of bacteriophage Qβ. Genetics 195:243-251. https://doi.org/10.1534/genetics.113.154963.
7. Gago S, Elena SF, Flores R, Sanjuan R. 2009. Extremely high mutation rate of a hammerhead viroid. Science 323:1308-1308. https://doi.org/10.1126/science.1169202.
8. Peris JB, Davis P, Cuevas JM, Nebot MR, Sanjuan R. 2010. Distribution of fitness effects caused by single-nucleotide substitutions in bacteriophage f1. Genetics 185:603-609. https://doi.org/10.1534/genetics.110.115162.
9. Malpica JM, Fraile A, Moreno I, Obies CI, Drake JW, Garcia-Arenal F. 2002. The rate and character of spontaneous mutation in an RNA virus. Genetics 162:1505-1511.
10. Elena SF, Moya A. 1999. Rate of deleterious mutation and the distribution of its effects on fitness in vesicular stomatitis virus. J Evol Biol 12:1078-1088. https://doi.org/10.1046/j.1420-9101.1999.00110.x.
11. Visher E, Whitefield SE, McCrone JT, Fitzsimmons W, Lauring AS. 2016. The mutational robustness of influenza A virus. PLoS Pathog 12: e1005856. https://doi.org/10.1371/journal.ppat.1005856.
12. Sanjuan R, Moya A, Elena SF. 2004. The distribution of fitness effects caused by single-nucleotide substitutions in an RNA virus. Proc Natl Acad Sci U S A 101:8396-8401. https://doi.org/10.1073/pnas.0400146101.
13. Eckerle LD, Becker MM, Halpin RA, Li K, Venter E, Lu X, Scherbakova S, Graham RL, Baric RS, Stockwell TB, Spiro DJ, Denison MR. 2010. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog 6:e1000896. https://doi.org/10.1371/journal.ppat.1000896.
14. Eckerle LD, Lu X, Sperry SM, Choi L, Denison MR. 2007. High fidelity of murine hepatitis virus replication is decreased in nsp14 exoribonuclease mutants. J Virol 81:12135-12144. https://doi.org/10.1128/JVI.01296-07.
15. Smith EC, Case JB, Blanc H, Isakov O, Shomron N, Vignuzzi M, Denison MR. 2015. Mutations in coronavirus nonstructural protein 10 decrease virus replication fidelity. J Virol 89:6418-6426. https://doi.org/10.1128/JVI.00110-15.
16. Smith EC, Blanc H, Surdel MC, Vignuzzi M, Denison MR. 2013. Coronaviruses lacking exoribonuclease activity are susceptible to lethal mutagenesis: evidence for proofreading and potential therapeutics. PLoS Pathog 9:e1003565. https://doi.org/10.1371/journal.ppat.1003565.
17. Sexton NR, Smith EC, Blanc H, Vignuzzi M, Peersen OB, Denison MR. 2016. Homology-based identification of a mutation in the coronavirus RNA-dependent RNA polymerase that confers resistance to multiple mutagens. J Virol 90:7415-7428. https://doi.org/10.1128/JVI.00080-16.
18. Arias A, Arnold JJ, Sierra M, Smidansky ED, Domingo E, Cameron CE. 2008. Determinants of RNA-dependent RNA polymerase (in)fidelity revealed by kinetic analysis of the polymerase encoded by a foot-andmouth disease virus mutant with reduced sensitivity to ribavirin. J Virol 82:12346-12355. https://doi.org/10.1128/JVI.01297-08.
19. Zeng J, Wang H, Xie X, Yang D, Zhou G, Yu L. 2013. An increased replication fidelity mutant of foot-and-mouth disease virus retains fitness in vitro and virulence in vivo. Antiviral Res 100:1-7. https://doi.org/10.1016/j.antiviral.2013.07.008.
20. Zeng J, Wang H, Xie X, Li C, Zhou G, Yang D, Yu L. 2014. Ribavirinresistant variants of foot-and-mouth disease virus: the effect of restricted quasispecies diversity on viral virulence. J Virol 88:4008-4020. https://doi.org/10.1128/JVI.03594-13.
21. Xie X, Wang H, Zeng J, Li C, Zhou G, Yang D, Yu L. 2014. Foot-and-mouth disease virus low-fidelity polymerase mutants are attenuated. Arch Virol 159:2641-2650. https://doi.org/10.1007/s00705-014-2126-z.
22. Sierra M, Airaksinen A, Gonzalez-Lopez C, Agudo R, Arias A, Domingo E. 2007. Foot-and-mouth disease virus mutant with decreased sensitivity to ribavirin: implications for error catastrophe. J Virol 81:2012-2024. https://doi.org/10.1128/JVI.01606-06.
23. Vignuzzi M, Stone JK, Arnold JJ, Cameron CE, Andino R. 2006. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439:344-348. https://doi.org/10.1038/nature04388.
24. Vignuzzi M, Wendt E, Andino R. 2008. Engineering attenuated virus vaccines by controlling replication fidelity. Nat Med 14:154-161. https://doi.org/10.1038/nm1726.
25. Pfeiffer JK, Kirkegaard K. 2003. A single mutation in poliovirus RNAdependent RNA polymerase confers resistance to mutagenic nucleotide analogs via increased fidelity. Proc Natl Acad Sci U S A 100:7289-7294. https://doi.org/10.1073/pnas.1232294100.
26. Arnold JJ, Vignuzzi M, Stone JK, Andino R, Cameron CE. 2005. Remote site control of an active site fidelity checkpoint in a viral RNA-dependent RNA polymerase. J Biol Chem 280:25706-25716. https://doi.org/10.1074/jbc.M503444200.
27. Liu X, Yang X, Lee CA, Moustafa IM, Smidansky ED, Lum D, Arnold JJ, Cameron CE, Boehr DD. 2013. Vaccine-derived mutation in motif D of poliovirus RNA-dependent RNA polymerase lowers nucleotide incorporation fidelity. J Biol Chem 288:32753-32765. https://doi.org/10.1074/jbc.M113.484428.
28. Weeks SA, Lee CA, Zhao Y, Smidansky ED, August A, Arnold JJ, Cameron CE. 2012. A polymerase mechanism-based strategy for viral attenuation and vaccine development. J Biol Chem 287:31618-31622. https://doi.org/10.1074/jbc.C112.401471.
29. Korboukh VK, Lee CA, Acevedo A, Vignuzzi M, Xiao Y, Arnold JJ, Hemperly S, Graci JD, August A, Andino R, Cameron CE. 2014. RNA virus population diversity, an optimum for maximal fitness and virulence. J Biol Chem 289:29531-29544. https://doi.org/10.1074/jbc.M114.592303.
30. Coffey LL, Beeharry Y, Borderia AV, Blanc H, Vignuzzi M. 2011. Arbovirus high fidelity variant loses fitness in mosquitoes and mice. Proc Natl Acad Sci U S A 108:16038-16043. https://doi.org/10.1073/pnas.1111650108.
31. Rozen-Gagnon K, Stapleford KA, Mongelli V, Blanc H, Failloux AB, Saleh MC, Vignuzzi M. 2014. Alphavirus mutator variants present host-specific defects and attenuation in mammalian and insect models. PLoS Pathog 10:e1003877. https://doi.org/10.1371/journal.ppat.1003877.
32. Cheung PPH, Watson SJ, Choy KT, Fun Sia S, Wong DDY, Poon LLM, Kellam P, Guan Y, Malik Peiris JS, Yen HL. 2014. Generation and characterization of influenza A viruses with altered polymerase fidelity. Nat Commun 5:4794. https://doi.org/10.1038/ncomms5794.
33. Gnadig NF, Beaucourt S, Campagnola G, Borderia AV, Sanz-Ramos M, Gong P, Blanc H, Peersen OB, Vignuzzi M. 2012. Coxsackievirus B3 mutator strains are attenuated in vivo. Proc Natl Acad Sci U S A 109: E2294-E2303. https://doi.org/10.1073/pnas.1204022109.
34. Campagnola G, McDonald S, Beaucourt S, Vignuzzi M, Peersen OB. 2015. Structure-function relationships underlying the replication fidelity of viral RNA-dependent RNA polymerases. J Virol 89:275-286. https://doi.org/10.1128/JVI.01574-14.
35. Sadeghipour S, McMinn PC. 2013. A study of the virulence in mice of high copying fidelity variants of human enterovirus 71. Virus Res 176: 265-272. https://doi.org/10.1016/j.virusres.2013.06.019.
36. Sadeghipour S, Bek EJ, McMinn PC. 2013. Ribavirin-resistant mutants of human enterovirus 71 express a high replication fidelity phenotype during growth in cell culture. J Virol 87:1759-1769. https://doi.org/10.1128/JVI.02139-12.
37. Meng T, Kwang J. 2014. Attenuation of human enterovirus 71 highreplication-fidelity variants in AG129 mice. J Virol 88:5803-5815. https://doi.org/10.1128/JVI.00289-14.
38. Graham RL, Becker MM, Eckerle LD, Bolles M, Denison MR, Baric RS. 2012. A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med 18:1820-1826. https://doi.org/10.1038/nm.2972.
39. Smith EC, Sexton NR, Denison MR. 2014. Thinking outside the triangle: replication fidelity of the largest RNA viruses. Annu Rev Virol 1:111-132. https://doi.org/10.1146/annurev-virology-031413-085507.
40. Gorbalenya AE, Enjuanes L, Ziebuhr J, Snijder EJ. 2006. Nidovirales: evolving the largest RNA virus genome. Virus Res 117:17-37. https://doi.org/10.1016/j.virusres.2006.01.017.
41. Brister JR, Ako-Adjei D, Bao Y, Blinkova O. 2014. NCBI viral genomes resource. Nucleic Acids Res 43:D571-D577. https://doi.org/10.1093/nar/gku1207.
42. Minskaia E, Hertzig T, Gorbalenya AE, Campanacci V, Cambillau C, Canard B, Ziebuhr J. 2006. Discovery of an RNA virus 3’->5’ exoribonuclease that is critically involved in coronavirus RNA synthesis. Proc Natl Acad Sci U S A 103:5108-5113. https://doi.org/10.1073/pnas.0508200103.
43. Snijder EJ, Bredenbeek PJ, Dobbe JC, Thiel V, Ziebuhr J, Poon LLM, Guan Y, Rozanov M, Spaan WJM, Gorbalenya AE. 2003. Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage. J Mol Biol 331:991-1004. https://doi.org/10.1016/S0022-2836(03)00865-9.
44. Ma Y, Wu L, Shaw N, Gao Y, Wang J, Sun Y, Lou Z, Yan L, Zhang R, Rao Z. 2015. Structural basis and functional analysis of the SARS coronavirus nsp14-nsp10 complex. Proc Natl Acad Sci U S A 112:9436-9441. https://doi.org/10.1073/pnas.1508686112.
45. Zuo Y, Deutscher MP. 2001. Exoribonuclease superfamilies: structural analysis and phylogenetic distribution. Nucleic Acids Res 29:1017-1026. https://doi.org/10.1093/nar/29.5.1017.
46. Bouvet M, Imbert I, Subissi L, Gluais L, Canard B, Decroly E. 2012. RNA 3’-end mismatch excision by the severe acute respiratory syndrome coronavirus nonstructural protein nsp10/nsp14 exoribonuclease complex. Proc Natl Acad Sci U S A 109:9372-9377. https://doi.org/10.1073/pnas.1201130109.
47. Yokomori K, Banner LR, Lai MMC. 1991. Heterogeneity of gene expression of the hemagglutinin-esterase (HE) protein of murine coronaviruses. Virology 183:647-657. https://doi.org/10.1016/0042-6822(91)90994-M.
48. Luytjes W, Bredenbeek PJ, Noten AF, Horzinek MC, Spaan WJ. 1988. Sequence of mouse hepatitis virus A59 mRNA 2: indications for RNA recombination between coronaviruses and influenza C virus. Virology 166:415-422. https://doi.org/10.1016/0042-6822(88)90512-0.
49. Yokomori K, Lai MM. 1991. Mouse hepatitis virus S RNA sequence reveals that nonstructural proteins ns4 and ns5a are not essential for murine coronavirus replication. J Virol 65:5605-5608.
50. Lissenberg A, Vrolijk MM, van Vliet ALW, Langereis MA, de Groot-Mijnes JDF, Rottier PJM, de Groot RJ. 2005. Luxury at a cost? Recombinant mouse hepatitis viruses expressing the accessory hemagglutinin esterase protein display reduced fitness in vitro. J Virol 79:15054-15063. https://doi.org/10.1128/JVI.79.24.15054-15063.2005.
51. Gadlage MJ, Graham RL, Denison MR. 2008. Murine coronaviruses encoding nsp2 at different genomic loci have altered replication, protein expression, and localization. J Virol 82:11964-11969. https://doi.org/10.1128/JVI.01126-07.
52. Zhao L, Jha BK, Wu A, Elliott R, Ziebuhr J, Gorbalenya AE, Silverman RH, Weiss SR. 2012. Antagonism of the interferon-induced OAS-RNase L pathway by murine coronavirus ns2 protein is required for virus replication and liver pathology. Cell Host Microbe 11:607-616. https://doi.org/10.1016/j.chom.2012.04.011.
53. Li Y, Weiss SR. 2016. Antagonism of RNase L is required for murine coronavirus replication in Kupffer cells and liver sinusoidal endothelial cells but not in hepatocytes. J Virol 90:9826-9832. https://doi.org/10.1128/JVI.01423-16.
54. Zhang R, Jha BK, Ogden KM, Dong B, Zhao L, Elliott R, Patton JT, Silverman RH, Weiss SR. 2013. Homologous 2’,5’-phosphodiesterases from disparate RNA viruses antagonize antiviral innate immunity. Proc Natl Acad Sci U S A 110:13114-13119. https://doi.org/10.1073/pnas.1306917110.
55. Sui B, Huang J, Jha BK, Yin P, Zhou M, Fu ZF, Silverman RH, Weiss SR, Peng G, Zhao L. 2016. Crystal structure of the mouse hepatitis virus ns2 phosphodiesterase domain that antagonizes RNase L activation. J Gen Virol 97:880-886. https://doi.org/10.1099/jgv.0.000395.
56. Schwarz B, Routledge E, Siddell SG. 1990. Murine coronavirus nonstructural protein ns2 is not essential for virus replication in transformed cells. J Virol 64:4784-4791.
57. Zhao L, Rose KM, Elliott R, Van Rooijen N, Weiss SR. 2011. Cell-type-specific type I interferon antagonism influences organ tropism of murine coronavirus. J Virol 85:10058-10068. https://doi.org/10.1128/JVI.05075-11.
58. Pereira-Gomez M, Sanjuan R. 2014. Delayed lysis confers resistance to the nucleoside analogue 5-fluorouracil and alleviates mutation accumulation in the single-stranded DNA bacteriophage φX174. J Virol 88: 5042-5049. https://doi.org/10.1128/JVI.02147-13.
59. Ng KKS, Arnold JJ, Cameron CE. 2008. Structure-function relationships among RNA-dependent RNA polymerases. Curr Top Microbiol Immunol 320:137-156. https://doi.org/10.1007/978-3-540-75157-1_7.
60. Brockway SM, Clay CT, Lu XT, Denison MR. 2003. Characterization of the expression, intracellular localization, and replication complex association of the putative mouse hepatitis virus RNA-dependent RNA polymerase. J Virol 77:10515-10527. https://doi.org/10.1128/JVI.77.19.10515-10527.2003.
61. Lehmann KC, Gulyaeva A, Zevenhoven-Dobbe JC, Janssen GMC, Ruben M, Overkleeft HS, van Veelen PA, Samborskiy DV, Kravchenko AA, Leontovich AM, Sidorov IA, Snijder EJ, Posthuma CC, Gorbalenya AE. 2015. Discovery of an essential nucleotidylating activity associated with a newly delineated conserved domain in the RNA polymerase-containing protein of all nidoviruses. Nucleic Acids Res 43:8416-8434. https://doi.org/10.1093/nar/gkv838.
62. Kelley LA, Mezulis S, Yates CM, Wass MN, Sternberg MJE. 2015. The Phyre2 web portal for protein modeling, prediction and analysis. Nat Protoc 10:845-858. https://doi.org/10.1038/nprot.2015.053.
63. Bouvet M, Lugari A, Posthuma CC, Zevenhoven JC, Bernard S, Betzi S, Imbert I, Canard B, Guillemot JC, Lecine P, Pfefferle S, Drosten C, Snijder EJ, Decroly E, Morelli X. 2014. Coronavirus Nsp10, a critical co-factor for activation of multiple replicative enzymes. J Biol Chem 289: 25783-25796. https://doi.org/10.1074/jbc.M114.577353.
64. Donaldson EF, Sims AC, Graham RL, Denison MR, Baric RS. 2007. Murine hepatitis virus replicase protein nsp10 is a critical regulator of viral RNA synthesis. J Virol 81:6356-6368. https://doi.org/10.1128/JVI.02805-06.
65. Crotty S, Cameron C, Andino R. 2002. Ribavirin’s antiviral mechanism of action: lethal mutagenesis? J Mol Med 80:86-95. https://doi.org/10.1007/s00109-001-0308-0.
66. Pathak VK, Temin HM. 1992. 5-Azacytidine and RNA secondary structure increase the retrovirus mutation rate. J Virol 66:3093-3100.
67. Carroll SS, Tomassini JE, Bosserman M, Getty K, Stahlhut MW, Eldrup AB, Bhat B, Hall D, Simcoe AL, LaFemina R, Rutkowski CA, Wolanski B, Yang Z, Migliaccio G, De Francesco R, Kuo LC, MacCoss M, Olsen DB. 2003. Inhibition of hepatitis C virus RNA replication by 2=-modified nucleoside analogs. J Biol Chem 278:11979-11984. https://doi.org/10.1074/jbc.M210914200.
68. Derbyshire V, Grindley ND, Joyce CM. 1991. The The 3’-5’ exonuclease of DNA polymerase I of Escherichia coli: contribution of each amino acid at the active site to the reaction. EMBO J 10:17-24.
69. Becares M, Pascual-Iglesias A, Nogales A, Sola I, Enjuanes L, Zuniga S. 2016. Mutagenesis of coronavirus nsp14 reveals its potential role in modulation of the innate immune response. J Virol 90:5399-5414. https://doi.org/10.1128/JVI.03259-15.
70. Cameron CE, Moustafa IM, Arnold JJ. 2016. Fidelity of nucleotide incorporation by the RNA-dependent RNA polymerase from poliovirus DNA replication across taxa, 1st ed. Elsevier Inc., New York, NY.
71. Subissi L, Posthuma CC, Collet A, Zevenhoven-Dobbe JC, Gorbalenya AE, Decroly E, Snijder EJ, Canard B, Imbert I. 2014. One severe acute respiratory syndrome coronavirus protein complex integrates processive RNA polymerase and exonuclease activities. Proc Natl Acad Sci U S A 111: E3900-E3909. https://doi.org/10.1073/pnas.1323705111.
72. Imbert I, Guillemot JC, Bourhis JM, Bussetta C, Coutard B, Egloff MP, Ferron F, Gorbalenya AE, Canard B. 2006. A second, non-canonical RNA-dependent RNA polymerase in SARS coronavirus. EMBO J 25: 4933-4942. https://doi.org/10.1038/sj.emboj.7601368.
73. Adedeji AO, Marchand B, Te Velthuis AJ, Snijder EJ, Weiss S, Eoff RL, Singh K, Sarafianos SG. 2012. Mechanism of nucleic acid unwinding by SARS-CoV helicase. PLoS One 7:e36521. https://doi.org/10.1371/journal.pone.0036521.
74. Chaudhuri M, Song L, Parris DS. 2003. The herpes simplex virus type 1 DNA polymerase processivity factor increases fidelity without altering pre-steady-state rate constants for polymerization or excision. J Biol Chem 278:8996-9004. https://doi.org/10.1074/jbc.M210023200.
75. Gu S, Li W, Zhang H, Fleming J, Yang W, Wang S, Wei W, Zhou J, Zhu G, Deng J, Hou J, Zhou Y, Lin S, Zhang XE, Bi L. 2016. The β2 clamp in the Mycobacterium tuberculosis DNA polymerase III αβ2ε replicase promotes polymerization and reduces exonuclease activity. Sci Rep 6:18418. https://doi.org/10.1038/srep18418.
76. Stapleford KA, Rozen-Gagnon K, Das PK, Saul S, Poirier EZ, Blanc H, Vidalain PO, Merits A, Vignuzzi M. 2015. Viral polymerase-helicase complexes regulate replication fidelity to overcome intracellular nucleotide depletion. J Virol 89:11233-11244. https://doi.org/10.1128/JVI.01553-15.
77. Agudo R, de la Higuera I, Arias A, Grande-Perez A, Domingo E. 2016. Involvement of a joker mutation in a polymerase-independent lethal mutagenesis escape mechanism. Virology 494:257-266. https://doi.org/10.1016/j.virol.2016.04.023.
78. Egloff MP, Ferron F, Campanacci V, Longhi S, Rancurel C, Dutartre H, Snijder EJ, Gorbalenya AE, Cambillau C, Canard B. 2004. The severe acute respiratory syndrome-coronavirus replicative protein nsp9 is a single-stranded RNA-binding subunit unique in the RNA virus world. Proc Natl Acad Sci U S A 101:3792-3796. https://doi.org/10.1073/pnas.0307877101.
79. Bhardwaj K, Guarino L, Kao CC. 2004. The severe acute respiratory syndrome coronavirus Nsp15 protein is an endoribonuclease that prefers manganese as a cofactor. J Virol 78:12218-12224. https://doi.org/10.1128/JVI.78.22.12218-12224.2004.
80. Sanjuan R, Cuevas JM, Furio V, Holmes EC, Moya A. 2007. Selection for robustness in mutagenized RNA viruses. PLoS Genet 3:e93. https://doi.org/10.1371/journal.pgen.0030093.
81. Goldhill D, Lee A, Williams ESCP, Turner PE. 2014. Evolvability and robustness in populations of RNA virus Φ6. Front Microbiol 5:35. https://doi.org/10.3389/fmicb.2014.00035.
82. Montville R, Froissart R, Remold SK, Tenaillon O, Turner PE. 2005. Evolution of mutational robustness in an RNA virus. PLoS Biol 3:e381. https://doi.org/10.1371/journal.pbio.0030381.
83. Lauring AS, Acevedo A, Cooper SB, Andino R. 2012. Codon usage determines the mutational robustness, evolutionary capacity, and virulence of an RNA virus. Cell Host Microbe 12:623-632. https://doi.org/10.1016/j.chom.2012.10.008.
84. Lauring AS, Frydman J, Andino R. 2013. The role of mutational robustness in RNA virus evolution. Nat Rev Microbiol 11:327-336. https://doi.org/10.1038/nrmicro3003.
85. Aguilera ER, Erickson AK, Jesudhasan PR, Robinson CM, Pfeiffer JK. 2017. Plaques formed by mutagenized viral populations have elevated coinfection frequencies. mBio 8:e02020-16. https://doi.org/10.1128/mBio.02020-16.
86. Graci JD, Gnadig NF, Galarraga JE, Castro C, Vignuzzi M, Cameron CE. 2012. Mutational robustness of an RNA virus influences sensitivity to lethal mutagenesis. J Virol 86:2869-2873. https://doi.org/10.1128/JVI.05712-11.
87. O’Dea EB, Keller TE, Wilke CO. 2010. Does mutational robustness inhibit extinction by lethal mutagenesis in viral populations? PLoS Comput Biol 6:e1000811. https://doi.org/10.1371/journal.pcbi.1000811.
88. Yount B, Denison MR, Weiss SR, Baric RS. 2002. Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol 76:11065-11078. https://doi.org/10.1128/JVI.76.21.11065-11078.2002.